RecruitingNCT06301191
The Effect of Semaglutide on Cardiovascular Markers and Liver Function
The Effect of Semaglutide on Endothelial Function, Arterial Stiffness and Liver Indices in Patients Witn Type 2 Diabetes Mellitus and NAFLD
Sponsor
Attikon Hospital
Enrollment
50 participants
Start Date
Mar 1, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Fifty patients with diabetes mellitus type 2 and non-alcoholic fatty liver disease (NAFLD) will be enrolled in the study. 25 patients will treated with semaglutide and 25 patients with dipeptidyl peptidase 4 (D-PP4) inhibitors. At baseline, at four and at 12 months will evaluate the endothelial, cardiovascular and liver function.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria2
- Diabetes Mellitus type 2
- NAFLD
Exclusion Criteria7
- malignancies
- chronic inflammatory disease
- chronic kidney disease (estimated glomerular filtration rate \<60 ml/min/m2 for a period of at least 90 days)
- peripheral vascular disease
- retinopathy
- previous therapy with a Glucagon-like peptide-1 agonist.
- None of the female patients was on hormone replacement treatment.
Interventions
DRUGSemaglutide, 1.0 mg/mL
Semaglutide, 1.0 mg/mL
DRUGDipeptidyl Peptidase 4 inhibitor
Dipeptidyl Peptidase 4 inhibitor
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06301191
Related Trials
Enhancing Digitally Delivered Diabetes Education With Real-Time CGM
NCT062965501 location
Disentangling the Effect of Brain Insulin Resistance on Brain Health
NCT073747053 locations
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
NCT059126471 location
Comparative Effectiveness of Prescribed Adapted Physical Activity (APA), Either Practiced Independently After Training, or Supervised by an APA Teacher, on Glycemic Regulation in People With Unbalanced Type 2 Diabetes.
NCT065988651 location
FELLAShip to Better Health
NCT072202131 location